Madrigal Pharmaceuticals, Inc. (MDGL) fair value analysis
Nasdaq · Updated 2026-10-19
MDGL price how computed
Valuation status
Awaiting full valuationMDGL's estimate rests on a sector-average price-to-earnings multiple, not on its own validated earnings history.
TickrTrends does not publish a borrowed multiple as a verdict. A verdict publishes automatically once MDGL's own trailing P/E history validates; every covered stock is re-evaluated weekly.
- Last price
- $449.74
- Sector
- Healthcare
- 12-month range
- $412.35–$602.83
- Market cap
- $10.4B
- From 52-week high
- -25.4%
- Shares outstanding
- 23.1M
- Rank in Healthcare by quality score
- #200 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of medicines for cardiovascular and metabolic diseases. The company operates in the United States and is headquartered in Conroe, Texas.
MDGL currently ranks #200 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $10.4B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $1.28B
- Net margin
- -25.3%
- EPS (TTM)
- $-10.90
- Gross margin
- 89.0%
- Debt / equity
- 0.66
- Shares outstanding
- 23.1M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Contracting
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 14 · oversold
- 50-day average
- $514.44
- 200-day average
- $505.11
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Next earnings report
- 2026-11-03
- Last 8 quarters vs consensus
- 6 beat, 2 missed
- Quarter by quarter
- 2026-06 ▲ beat (+22.0%)
2026-03 ▲ beat (+66.7%)
2025-12 ▼ miss (-325.6%)
2025-09 ▼ miss (-149.2%)
2025-06 ▲ beat (+46.2%)
2025-03 ▲ beat (+12.4%)
2024-12 ▲ beat (+34.3%)
2024-09 ▲ beat (+28.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 18 buy · 1 hold · 0 sell (19 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $686
- Target vs last price
- +52.5%
What our data shows for MDGL
- Shares are trading in the lower third of their 12-month price range of $412.35–$602.83.
- The 14-day relative strength index sits at an oversold 14.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- MDGL's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent MDGL news
TickrTrends' derived news-sentiment signal for MDGL is currently leaning positive, computed from recent coverage.
- Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight (manilatimes.net, 2026-10-21)
- MDGL Reinstated by Goldman Sachs -- Price Target Announced at $704 (gurufocus.com, 2026-09-24)
- Goldman Sachs Reinitiates Coverage on Madrigal Pharmaceuticals (MDGL) with Buy Rating and $704 Price Target (gurufocus.com, 2026-09-24)
More MDGL news
- Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) (manilatimes.net, 2026-09-16)
What people are saying
Follow the MDGL conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for MDGL show a deterioration in quality assessment this week, with the quality grade declining from D to F. The relative strength index zone has shifted from neutral to oversold, indicating intensified downward momentum in the stock. The valuation verdict remains awaiting full valuation.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — MDGL's 50/200-day trend state shifted from uptrend to mixed this week, indicating a change in the company's recent momentum relative to its longer-term trajectory. The stock's derived indicators now reflect a less clearly directional pattern compared to the prior week's uptrend classification. The valuation assessment for this Healthcare sector company remains under review pending additional analysis.
- 2026-09-21 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is MDGL stock undervalued?
MDGL's estimate rests on a sector-average price-to-earnings multiple rather than its own validated earnings history, and TickrTrends does not publish a borrowed multiple as a verdict. It is re-evaluated every week.
What is MDGL's TickrTrends verdict?
MDGL is currently marked 'Awaiting full valuation' - a verdict publishes automatically once MDGL's own trailing P/E history validates under our standards.
How does MDGL compare to other Healthcare stocks?
MDGL ranks #200 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is MDGL overbought or oversold?
MDGL's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does MDGL report earnings next?
MDGL's next earnings report is scheduled for 2026-11-03, per the published earnings calendar.
Does MDGL usually beat earnings estimates?
Over its last 8 reported quarters MDGL beat the consensus estimate 6 times and missed 2 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MDGL?
Of 19 analysts covering MDGL, 18 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $686 (+52.5% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.